Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer
| Autor: | Keval M. Patel, Charles E. Massie, Vincent J. Gnanapragasam, Tim Forshew, K. E. van der Vos, Florent Mouliere, Francesco Marass, Dana W.Y. Tsui, Dineika Chandrananda, M.S. van der Heijden, D. Van Den Broek, James Morris, Nitzan Rosenfeld, David E. Neal, B.W.G. Van Rhijn, Christopher Smith |
|---|---|
| Přispěvatelé: | Pathology, Smith, Christopher [0000-0001-7357-2737], Mouliere, Florent [0000-0001-7043-0514], Chandrananda, Sandunie [0000-0002-8834-9500], Gnanapragasam, Vincent [0000-0003-4722-4207], Massie, Charles [0000-0003-2314-4843], Rosenfeld, Nitzan [0000-0002-2825-4788], Apollo - University of Cambridge Repository |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Pathology Science Urinary system medicine.medical_treatment Urine Gastroenterology Article 03 medical and health sciences Internal medicine medicine Humans Liquid biopsy Neoadjuvant therapy Aged Body fluid Chemotherapy Multidisciplinary Bladder cancer business.industry Genome Human DNA Neoplasm Middle Aged medicine.disease Neoadjuvant Therapy 3. Good health 030104 developmental biology Treatment Outcome Urinary Bladder Neoplasms Mutation Medicine Biomarker (medicine) Female Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Scientific Reports Scientific Reports, 7(1):5554. Nature Publishing Group Patel, K M, Van Der Vos, K E, Smith, C G, Mouliere, F, Tsui, D, Morris, J A, Chandrananda, D, Marass, F, Van Den Broek, D, Neal, D E, Gnanapragasam, V J, Forshew, T, Van Rhijn, B W, Massie, C E, Rosenfeld, N & Van Der Heijden, M S 2017, ' Association of Plasma and Urinary Mutant DNA with Clinical Outcomes in Muscle Invasive Bladder Cancer ', Scientific Reports, vol. 7, no. 1, 5554 . https://doi.org/10.1038/s41598-017-05623-3 Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017) |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-017-05623-3 |
| Popis: | Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve a 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, from 17 patients undergoing NAC. We assessed single nucleotide variants and copy number alterations in mutDNA using Tagged-Amplicon- and shallow Whole Genome- Sequencing. MutDNA was detected in 35.3%, 47.1% and 52.9% of pre-NAC plasma, UCP and USN samples respectively, and urine samples contained higher levels of mutDNA (p = |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|